



Pharma Mar group revenues totalled €140 million in the first nine months of the year

- **Group EBITDA improved with respect to the same period last year**
- **The Group net attributable loss improved +13% compared to 2016**

Madrid, 24th October, 2017: The Pharma Mar (MSE: PHM) group registered total net sales of €140 million in the first nine months of 2017, a 0.6% increase with respect to the same period last year. Total revenues in the oncology segment (sales plus royalties and licensing revenues) amounted to €75.6 million, 0.2% more to the same period last year (€75.4 million).

Yondelis[®] sales amounted to €64.6 million, slightly less than in the same period of 2016 due primarily to price erosion in some European countries; Yondelis[®] royalties from our partners amounted to €3.9 million and licensing revenues to €7.1 million. The consumer chemicals division reported a 2.1% increase in revenues to €60.4 million.

Group EBITDA improved an 18% in the first nine months of 2017 to -€4.6 million, compared with -€5.6 million in the same period of 2016. This was due mainly to containment of operating expenses (R&D, marketing and commercial, administration, etc.), which fell 2.3% in the first nine months. This improvement in operating costs was achieved without modifying the existing operating plan or the clinical trial programs. Enrolment continues for the Phase III trial with Zepsyre[®] in small cell lung cancer, which is expected to complete enrolment next year. Also, the Committee for Medicinal Products for Human Use (CHMP) is expected to give their opinion by year-end to the Marketing Authorization Application (MAA) for Aplidin[®] in Europe for the treatment of multiple myeloma. And the outcome of the Phase III trial with Zepsyre[®] in platinum-resistant ovarian cancer is expected early next year.



As a result, the Group reported a net attributable loss of -€14.53 million in the first nine months of 2017, compared with -€16.6 million in the same period of 2016.

About PharmaMar

PharmaMar, a Madrid-based biopharmaceutical company, is a world leader in discovering, developing and marketing anti-tumour drugs obtained from the sea. PharmaMar has a rich pipeline of pre-clinical candidates and a major R&D programme. The company develops and markets YONDELIS® in Europe and has other compounds in clinical development for treating solid and haematological tumours: plitidepsin (Aplidin®), PM1183 (Zepsyre®), PM184 and PM14. PharmaMar is a global biopharmaceutical company with a presence in Germany, Italy, France, Switzerland, the United Kingdom, Belgium and the USA. PharmaMar also has a majority stake in other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, focused on developing therapeutic applications of gene silencing (RNAi); and two chemical companies: Zelnova Zeltia and Xylazel. For more information, visit our website: www.pharmamar.com

Important note

This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe for shares of the company. Moreover, no reliance should be placed upon this document or its distribution for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the Company.

Further information from:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile : + 34609493127
Paula Fernández – Media Relations Manager pfalarcon@pharmamar.com Mobile: +34 638796215
Phone: +34 918466000



Investor relations:

José Luis Moreno Martínez-Losa – Head of Investor Relations and Capital Markets

investorrelations@pharmamar.com

Phone: +34 914444500

For more information, visit our website: www.pharmamar.com

###